Effective as of July 9, 2021, James Levine resigned from his position as the Chief Financial Officer, including as the principal financial officer and principal accounting officer, of Cidara Therapeutics, Inc. (the “Company”). Mr. Levine resigned from the company in order to pursue other opportunities. Effective as of the date of Mr. Levine’s resignation, Jeffrey L. Stein, President and Chief Executive Officer of the Company, will assume the role of the company’s principal financial officer, and Brady Johnson will be promoted to Vice President, Finance and assume the role of the company’s principal accounting officer. There will be no change to Dr. Stein’s or Mr. Johnson’s compensation arrangements with the Company as a result of their respective appointments. Mr. Levine has agreed to serve as a consultant to the Company for at least the six month period following his resignation to assist with a smooth transition of his duties, and his Company equity awards will continue to vest during such period of transition services.